Düsseldorf The pharmaceutical company Modern wants governments to charge between $ 25 and $ 37 for a dose of his Covid vaccine. “That is a fair price when you consider how high the costs are for the health system if a person becomes seriously ill with Covid-19,” said CEO Stephane Bancel of “Welt am Sonntag” according to the preliminary report. “We are not concerned with the maximum profit.” On Monday, EU circles reported that they wanted to buy millions of cans from Moderna for a unit price of less than 25 dollars.
The US company assumes that it will be able to produce around 20 million doses of the vaccine this year. However, these should only be intended for the US market. The American company plans to produce 500 million to one billion units in the coming year.
A week after the Mainz biotech company Biontech, the competitor Moderna also presented very good interim results for its corona vaccine candidate last week. This is based – just like that of Biontech – on the new messenger RNA technology (mRNA).
The vaccine tested by Moderna in a large study showed an effectiveness of 94.5 percent – and thus possibly even better results than the vaccine from Biontech, which according to Biontech reduces the risk of Covid-19 by more than 90 percent .
This shows that before the end of the year, at least in the USA, several vaccines could be available to vaccinate the first groups of people against the Sars-CoV2 virus. The Moderna data were derived from a partial evaluation of the ongoing study, which included more than 30,000 participants.
According to Moderna, of a total of 95 cases of infection that were analyzed for the interim evaluation, 90 were people who had received a sham vaccine (placebo) and only five were study participants who had actually received the vaccine. Just like the Biontech results, the results of Moderna significantly exceed earlier expectations of potential Covid vaccines.
EU Commission chief Ursula Von der Leyen said at the end of last week that the vaccines from Biontec and Pfizer and could get a conditional marketing authorization from Moderna in the second half of December – if everything goes on without any problems.
More: Follow the current developments in the corona crisis in our news blog.